Jonathan Bramson
McMaster University
H-index: 59
North America-Canada
Top articles of Jonathan Bramson
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Endogenous CD28 drives CAR T cell responses in multiple myeloma | bioRxiv | Mackenzie M Lieberman Jason H Tong Nkechi U Odukwe Colin A Chavel Terence J Purdon | 2024/3/24 |
T cell-antigen coupler with various construct optimizations | 2024/1/23 | ||
Cells comprising t cell-antigen couplers and uses thereof | 2024/1/18 | ||
Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells | Journal for Immunotherapy of Cancer | Jordon M Inkol Michael J Westerveld Shayla G Verburg Scott R Walsh Jodi Morrison | 2024 |
Covalent immune recruiter compounds for immune cell recognition and associated uses | 2023/11/28 | ||
LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses | Blood | Yu Yan Kanwaldeep Singh Emily Hartung Brendan Lee Pradhariny Prabagaran | 2023/11/28 |
T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma | Cytotherapy | Ksenia Bezverbnaya Joanne A Hammill Derek Cummings Bojana Bojovic Bella Groisman | 2023/5/1 |
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy | Communications Biology | Amr Ali Bassem Mekhaeil Olga-Demetra Biziotis Evangelia E Tsakiridis Elham Ahmadi | 2023/9/8 |
290 IL-15 is required for optimal anti-tumor activity of Vγ9Vδ2 T cells against glioblastoma | Allyson E Moore Nickolas Serniuck Arya Afsahi Hayley Nault Sheila K Singh | 2023/11/1 | |
Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada | Journal of the American Medical Directors Association | Jessica A Breznik Ahmad Rahim Tara Kajaks Megan Hagerman Lucas Bilaver | 2023/5/1 |
Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities | EClinicalMedicine | Jessica A Breznik Ahmad Rahim Ali Zhang Jann Ang Hannah D Stacey | 2023/9/1 |
Protocol for a longitudinal cohort study of Lyme disease with physical, mental and immunological assessment | BMJ open | Mark Loeb Robert Brison Jonathan Bramson Todd Hatchette Beate Sander | 2023/11/1 |
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α | Molecular Oncology | Olga‐Demetra Biziotis Evangelia Evelyn Tsakiridis Amr Ali Elham Ahmadi Jianhan Wu | 2023/11 |
LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling | Frontiers in Immunology | Arya Afsahi Christopher M Silvestri Allyson E Moore Carly F Graham Kaylyn Bacchiochi | 2023/4/17 |
Constitutive expression of interleukin-27 diminishes proinflammatory cytokine production without impairing effector function of engineered T cells | Cytotherapy | Arya Afsahi Rebecca Burchett Christopher L Baker Allyson E Moore Jonathan L Bramson | 2023/6/10 |
HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion | Clinical Cancer Research | Andrew Nguyen Dominique Brown Ramya Krishnan Donald Bastin Li Deng | 2023/10/13 |
Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory … | Cancer Research | Quincy Chu Tudor Ciuleanu Rodryg Ramlau Daniel Renouf Rosalyn Juergens | 2023/4/14 |
T cell-antigen coupler with y182t mutation and methods of uses thereof | 2023/8/24 | ||
Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis | Scientific Reports | Jenna M Benoit Jessica A Breznik Jann C Ang Hina Bhakta Angela Huynh | 2023/12/21 |
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). | Aly-Khan A Lalani Anand Swaminath Gregory Russell Pond Scott C Morgan Arun Azad | 2023/2/20 |
